Diagnosis, treatment management, and challenges in neurofibromatosis type 1: a case report with mixed features
Open Access
- 18 December 2025
- journal article
- case report
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1907-1912
Abstract
Introduction: Neurofibromatosis type 1 (NF1) is a prevalent genetic disorder; however, the incidence of plexiform neurofibromas remains relatively low. This article presents a case of mixed-type NF1 with plexiform neurofibroma. Case Presentation: Following domestic and international expert consensus, a multidisciplinary team conducted a comprehensive evaluation and formulated an individualized treatment plan. Although the diagnosis of NF1 was confirmed, the precise origin of the massive superficial mass in the child remains uncertain. Clinical Discussion: This study provides a comprehensive exploration of the clinical manifestations and theoretical underpinnings that facilitate the precise diagnosis, treatment, and long-term management of patients with NF1. Conclusion: In conclusion, the clinical management of pediatric NF1 patients is complex as therapeutic interventions are not for all. Due to heterogeneous manifestations and variable disease trajectories, there is no standardized treatment algorithm. Integrating molecular diagnostics, targeted therapies, and multidisciplinary care is crucial for personalized and effective long – term management of those with this genetic disorder.Keywords
This publication has 23 references indexed in Scilit:
- Treatment With Selumetinib for Café-au-Lait Macules and Plexiform Neurofibroma in Pediatric Patients With Neurofibromatosis Type 1JAMA Dermatology, 2024
- Neurofibromatosis Type 1 and Risk of Skin CancerJAMA Dermatology, 2022
- Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive reviewESMO Open, 2021
- Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendationGenetics in Medicine, 2021
- New therapy for children with plexiform neurofibromasThe Lancet Oncology, 2020
- An update on the central nervous system manifestations of neurofibromatosis type 1Acta Neuropathologica, 2019
- Absence of Efficacy of Everolimus in Neurofibromatosis 1-Related Plexiform Neurofibromas: Results from a Phase 2a TrialJournal of Investigative Dermatology, 2019
- Pediatric malignancies in neurofibromatosis type 1: A population‐based cohort studyInternational Journal of Cancer, 2019
- Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm TrialDrugs in R&D, 2018
- Neurofibromatosis type 1: a multidisciplinary approach to careThe Lancet Neurology, 2014